Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
9.64
-0.71 (-6.86%)
Nov 20, 2024, 4:00 PM EST - Market closed
Alumis Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
109
Market Cap
524.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionALMS News
- 7 days ago - Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements - GlobeNewsWire
- 4 weeks ago - Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside - Benzinga
- 6 weeks ago - Alumis: Could This Broken Immunology IPO Become The Next Amgen? - Seeking Alpha
- 7 weeks ago - Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study - GlobeNewsWire
- 2 months ago - Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases - Seeking Alpha
- 2 months ago - Alumis to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 3 months ago - Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - GlobeNewsWire
- 4 months ago - Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis - GlobeNewsWire